NovaBay Pharmaceuticals, Inc. Releases 2025 Annual Report: What Investors Need to Know

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) has filed its Annual Report (Form 10-K) for the fiscal year ended December 31, 2025. The report includes a comprehensive breakdown of the company’s financial position, equity structure, recent capital market activities, and various securities issued in the past year. Below, we highlight the key takeaways and critical items that could influence shareholder value and market sentiment.

Key Points from the 2025 Annual Report

• Fiscal Year End: December 31, 2025
• Report Filed: March 19, 2026
• Corporate Address: 2000 Powell Street, Suite 1150, Emeryville, CA 94608
• Industry: Pharmaceutical Preparations (SIC: 2834)
• SEC File Number: 001-33678

1. Equity Structure: Multiple Preferred Stock and Warrant Transactions

NovaBay’s capital structure has become increasingly complex, with numerous transactions involving different series of preferred stocks (Series B, C, D, E, F), common stock, and a variety of warrants issued and/or repriced during 2024 and 2025. Shareholders should take note of the following:

• Preferred Stock Conversions:
  • Significant conversions of Series B, C, D, and E Preferred Stock into Common Stock during the period. These conversions can be dilutive and may impact share value depending on conversion ratios and timing.
• Warrant Issuances and Repricing:
  • Multiple classes of warrants, including Series F1, F2, F3, and the December 2023, March 2024, and other series, have been issued and in some cases repriced or amended. These instruments, if exercised, may significantly increase the outstanding share count.
  • Warrants tied to recent public offerings and private placements may have adjustment or ratchet features that could trigger further dilution under certain circumstances.
• Convertible Notes:
  • Unsecured convertible notes outstanding, with measurement inputs (dividend rate, risk-free rate, volatility, share price, exercise price) detailed for fair value calculations. These notes could convert into equity, further increasing dilution risk.

2. Significant Capital Market Activities in 2024-2025

• 2024 Public Offering:
  • Issuance of Series F Warrants and Prefunded Warrants as part of a capital raise. The participation of underwriters and over-allotment options was noted, which may impact post-offering share counts.
  • The company has entered into “at the market” (ATM) offering agreements, allowing for ongoing capital raises that could be tapped as needed, potentially exerting downward pressure on the share price if used extensively.
• Private Placements and Preferred Stock Purchase Agreements:
  • Several series of preferred stock (D, E, F, etc.) and related warrants were issued via private placements. These placements often include conversion and anti-dilution provisions that may affect future share counts.

3. Dilution and Ownership Structure: Critical Considerations for Shareholders

• Frequent Issuance and Conversion of Equity Instruments: The persistent use of preferred stock, warrants, and convertible notes increases the risk of dilution for common shareholders. The timing and terms of conversions or exercises (including ratchets, resets, and repricing events) are price-sensitive and may lead to sharp changes in share value.
• Complex Capital Stack: The company’s equity and debt structure has become highly layered, which can make it challenging for investors to track true ownership and potential dilution. This complexity could also affect market perception and investor confidence.

4. Price-Sensitive and Market Moving Information

• Convertible Securities with Ratchet/Adjustment Provisions: Several securities contain ratchet or adjustment mechanisms that could result in the automatic repricing of warrants or conversion ratios in the event of future financings or share price declines. Such provisions can be highly dilutive and are often closely watched by the market for their potential to impact share value.
• Ongoing ATM Offerings and Over-Allotment Options: The company’s ability to issue new shares at market prices on a rolling basis gives management flexibility but can also cap near-term share price appreciation, as investors may anticipate further dilution.
• Multiple Classes of Securities Outstanding: The interplay between preferred stock, common stock, warrants, and convertible notes means that significant changes to one class (e.g., a large conversion or exercise event) can have cascading effects on others, potentially leading to volatility in the common share price.

5. Details for Investors: What to Watch Going Forward

• Monitor SEC Filings for New Offerings or Conversions: Given the company’s ongoing use of complex capital market instruments, any new S-1, S-3, or 8-K filings announcing new deals, conversions, or amendments could quickly affect share value.
• Review Terms of Outstanding Warrants and Notes: Investors should pay close attention to the terms (especially repricing, anti-dilution, and ratchet clauses) of all outstanding warrants and convertible notes, as these can create sudden increases in outstanding share count.
• Track ATM and Public Offering Activity: Regular updates on sales through ATM programs and participation in public offerings will be material to forecasting future dilution and capital structure.

Conclusion

NovaBay Pharmaceuticals, Inc.’s 2025 Annual Report reveals a company heavily reliant on equity-linked financing, with a complex and evolving capital structure. The issuance, conversion, repricing, and ratcheting of preferred stock, warrants, and convertible notes introduce significant dilution risk for common shareholders and can be highly price-sensitive. Investors are advised to closely monitor future SEC filings and company announcements for developments regarding these instruments, as they have the potential to move the share price both positively and negatively depending on market interpretation and the specifics of each transaction.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information herein is based solely on the company’s 2025 Annual Report as filed with the SEC and may not reflect the most current events or market conditions.

View NovaBay Pharmaceuticals, Inc. Historical chart here